Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol Could Be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 Diabetes

Overview

Journal J Atheroscler Thromb

Date 2024 Sep 4

PMID 39231648

Authors

Tsutomu Hirano

Affiliations

Soon will be listed here.

Abstract

Aims: We report that small dense low-density lipoprotein cholesterol (sdLDL-C) levels are sensitive biomarkers of metabolic dysfunction-associated steatotic liver disease (MASLD). Since triglyceride (TG)-rich very low-density lipoprotein (VLDL) is a precursor of sdLDL and is overproduced by MASLD, the composition of VLDL may be more directly associated with MAFLD than sdLDL-C or plasma TG. To identify TG-rich VLDL, this author proposed "Excess TG" and examined its association with MASLD.

Methods: Patients with type 2 diabetes (n=1295), excluding fasting hypertriglyceridemia (TG ≥ 400 mg/dL) and heavy drinkers were examined. Liver steatosis and visceral fat area (VFA) were evaluated using CT. VLDL-C was calculated as the total C minus direct LDL-C minus HDL-C. The average VLDL-TG level can be estimated using VLDL-C×5, according to the principle of the Friedewald equation for LDL-C. Thus, VLDL-TG was estimated as VLDL-C×5, and Excess TG was calculated as plasma TG minus VLDL-C×5.

Results: Patients with MASLD were younger, more likely to be men and drinkers, and had higher VFA, TG, sdLDL-C, and excess TG, while VLDL-C was comparable. Excess TG was found to be the most sensitive lipid parameter for identifying MASLD, independent of sdLDL-C, TG, TG/VLDL-C, and VFA. The odds ratios for MASLD were 2.4-, 3.7-, and 3.9-fold higher for Excess TG ranges of 0-24, 25-49, and ≥ 50 mg/dL, respectively, relative to ＜0 mg, and a close relationship remained significant after adjustment for lipid- and adiposity-related parameters.

Conclusions: Excess TG in VLDL was strongly associated with MASLD beyond TG and sdLDL-C levels, which may reflect the presence of TG-rich VLDL.

References

Austin M . Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991; 11(1):2-14. DOI: 10.1161/01.atv.11.1.2. View

Boren J, Adiels M, Bjornson E, Matikainen N, Soderlund S, Ramo J . Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight. 2020; 5(24). PMC: 7819740. DOI: 10.1172/jci.insight.144079. View

Santos-Baez L, Ginsberg H . Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Curr Opin Lipidol. 2021; 32(3):200-206. PMC: 8087156. DOI: 10.1097/MOL.0000000000000756. View

Stahl E, Dhindsa D, Lee S, Sandesara P, Chalasani N, Sperling L . Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73(8):948-963. DOI: 10.1016/j.jacc.2018.11.050. View

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023; 29(1):101133. DOI: 10.1016/j.aohep.2023.101133. View

Nordestgaard B . Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016; 118(4):547-63. DOI: 10.1161/CIRCRESAHA.115.306249. View

Mannisto V, Simonen M, Soininen P, Tiainen M, Kangas A, Kaminska D . Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res. 2014; 55(12):2676-84. PMC: 4242459. DOI: 10.1194/jlr.P054387. View

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Alomari M, Rashid M, Chadalavada P, Ragheb J, Zafar H, Suarez Z . Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes. World J Hepatol. 2023; 15(4):477-496. PMC: 10190689. DOI: 10.4254/wjh.v15.i4.477. View

10.

Martin S, Blaha M, Elshazly M, Toth P, Kwiterovich P, Blumenthal R . Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013; 310(19):2061-8. PMC: 4226221. DOI: 10.1001/jama.2013.280532. View

11.

Boren J, Watts G, Adiels M, Soderlund S, Chan D, Hakkarainen A . Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study. Arterioscler Thromb Vasc Biol. 2015; 35(10):2218-24. DOI: 10.1161/ATVBAHA.115.305614. View

12.

Adiels M, Taskinen M, Packard C, Caslake M, Soro-Paavonen A, Westerbacka J . Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006; 49(4):755-65. DOI: 10.1007/s00125-005-0125-z. View

13.

Gill J, Brown J, Bedford D, Wright D, Cooney J, Hughes D . Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis. 2004; 176(1):49-56. DOI: 10.1016/j.atherosclerosis.2004.04.022. View

14.

Hirano T, Satoh N, Kodera R, Hirashima T, Suzuki N, Aoki E . Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort. J Diabetes Investig. 2021; 13(4):657-667. PMC: 9017612. DOI: 10.1111/jdi.13697. View

15.

Miller W, Myers G, Sakurabayashi I, Bachmann L, Caudill S, Dziekonski A . Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010; 56(6):977-86. PMC: 4687457. DOI: 10.1373/clinchem.2009.142810. View

16.

Packard C, Shepherd J . Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1998; 17(12):3542-56. DOI: 10.1161/01.atv.17.12.3542. View

17.

Chen J, Fang Z, Luo Q, Wang X, Warda M, Das A . Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. Lipids Health Dis. 2024; 23(1):14. PMC: 10785355. DOI: 10.1186/s12944-023-01993-y. View

18.

Berneis K, Krauss R . Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002; 43(9):1363-79. DOI: 10.1194/jlr.r200004-jlr200. View

19.

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

20.

Ito Y, Ohta M, Ikezaki H, Hirao Y, Machida A, Schaefer E . Development and Population Results of a Fully Automated Homogeneous Assay for LDL Triglyceride. J Appl Lab Med. 2021; 2(5):746-756. DOI: 10.1373/jalm.2017.024554. View